SCHEMBL4112277

SCHEMBL4112277

CCCOc1ccc(NC(=O)Nc2ccc(Cl)cc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 5/20 0.72
EPHX2 P34913 2/20 0.59
MEN1 O00255 4/20 0.58
KMT2A Q03164 4/20 0.58
CA12 O43570 2/20 0.58
CA1 P00915 2/20 0.58
CA2 P00918 2/20 0.58
CA9 Q16790 2/20 0.58
ALDH1A1 P00352 5/20 0.58
NPC1 O15118 2/20 0.58
LMNA P02545 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
RAB9A P51151 2/20 0.58
NFKB1 P19838 1/20 0.58
CASP3 P42574 1/20 0.58
NFKB2 Q00653 1/20 0.58
RELA Q04206 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
SENP8 Q96LD8 1/20 0.58
SENP7 Q9BQF6 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4922767 0.94 HRH3 (0.72) HRH3EPHX2MEN1KMT2ACA12
SCHEMBL4117849 0.87 MAPT (0.73) HRH3MEN1KMT2AALDH1A1NPC1
SCHEMBL4118335 0.86 MAPT (0.67) EPHX2MEN1KMT2ACA12CA1
SCHEMBL4124890 0.86 EPHX2 (0.60) HRH3EPHX2MEN1KMT2ACA12
SCHEMBL4104949 0.86 PPARA (0.68) EPHX2CA12CA1CA2CA9
SCHEMBL4113295 0.86 RAB9A (0.71) EPHX2MEN1KMT2ACA12CA1
SCHEMBL4105911 0.85 RAB9A (0.66) HRH3EPHX2MEN1KMT2ACA12
SCHEMBL4113719 0.84 EPHX2 (0.59) HRH3EPHX2MEN1KMT2ACA12
SCHEMBL4106567 0.84 FAAH (0.68) HRH3EPHX2MEN1KMT2ACA12
SCHEMBL4112694 0.83 MAPT (0.62) EPHX2MEN1KMT2ACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 HRH3 208/4885EPHX2 2394/4885MEN1 3273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.